Przegla̜d Gastroenterologiczny最新文献

{"title":"Gallstone ileus: a case report of small bowel obstruction.","authors":"Andreas Antzoulas, George Theofanis, Chrysa Andrikopoulou, Vasileios Leivaditis, Dimitrios Litsas, Panagiotis Dimitrios Papadopoulos, Konstantinos Tasios, Apostolos Panagopoulos, Theodora Skoura, Nina Miteva, Ioannis Maroulis, Francesk Mulita","doi":"10.5114/pg.2026.161901","DOIUrl":"10.5114/pg.2026.161901","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 2","pages":"228-232"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction.","authors":"Inga M Świątek, Iwona Gorczyca-Głowacka, Dorota Zarębska-Michaluk","doi":"10.5114/pg.2026.161894","DOIUrl":"10.5114/pg.2026.161894","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with heart failure with preserved ejection fraction (HFpEF), driven by systemic inflammation, insulin resistance, and oxidative stress, which are shared pathophysiological mechanisms. HFpEF and MASLD often co-occur, especially in patients with conditions like obesity and type 2 diabetes mellitus (T2DM). The increasing global prevalence of both MASLD and HFpEF emphasises their shared risk factors and clinical implications. Early diagnosis and a multidisciplinary approach are important in the management of these interconnected diseases. Treatment strategies like the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have shown promise in addressing both conditions, improving liver steatosis, and reducing heart failure risk. Targeted therapies and lifestyle modifications are fundamental to managing MASLD and HFpEF, given their overlapping pathophysiology and impact on patient outcomes.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 2","pages":"119-125"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global trend of organoid implementation for hepatocellular carcinoma research (2005-2024): bibliometric analysis.","authors":"Changsheng Ji, Hui Zhao, Ying Shui, Wangpeng Zhao, Lishuai Qu","doi":"10.5114/pg.2026.160529","DOIUrl":"10.5114/pg.2026.160529","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, organoids have been increasingly used in the study of hepatocellular carcinoma (HCC). The purpose of this study is to analyse the research field of HCC organoids through bibliometrics, and to determine the key themes, trends, and contributions in this field.</p><p><strong>Aim: </strong>This study analyses global HCC organoid research trends from 2005 to 2024 to identify key developments and future directions.</p><p><strong>Material and methods: </strong>We screened literature on HCC and organoids from the Web of Science Core Collection (WOSCC) database from 2005 to 2024. CiteSpace and VOSviewer were used to visualise the bibliometric indicators.</p><p><strong>Results: </strong>The 267 articles analysed in this study came from 630 institutions in 40 countries/regions and were published in 149 journals. From 2005 to 2015, the number of publications continued to be low, and then entered a stage of rapid growth in 2016. The top three countries with the largest number of publications were China (128; 47.94%), the United States (65; 24.34%), and Germany (27; 10.11%). <i>International Journal of Molecular Sciences</i> is the journal with the largest number of publications. Van Der Laan Luc J. W. was the most prolific author.</p><p><strong>Conclusions: </strong>HCC organoid research has grown significantly, led by China, the United States, and Germany, focusing on model optimisation, molecular mechanisms, targeted therapy, and drug resistance, with emerging trends in long-term culture systems and patient-derived organoids.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 1","pages":"55-72"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women in gastroenterology: what is the current situation? Results of a Polish National Survey.","authors":"Włodarczyk Aleksandra Sobolewska-, Sukiennik Aleksandra Jagura-, Julia Wawerska, Anita Gąsiorowska","doi":"10.5114/pg.2026.160373","DOIUrl":"10.5114/pg.2026.160373","url":null,"abstract":"<p><strong>Introduction: </strong>The number of women graduating from medical school is on the rise, and in Poland, there is a notable feminisation in the physician profession. In 2023, out of 156,290 practicing physicians, 92,421 were women (59.13%). Female gastroenterologists face numerous challenges during their training, including gender-based prejudice, physical demands of endoscopic procedures, and standardised equipment not designed for smaller hands.</p><p><strong>Aim: </strong>The study aimed to characterise female gastroenterologists and trainees in Poland and identify potential problems and difficulties in their daily work.</p><p><strong>Material and methods: </strong>A web-based, voluntary, anonymous questionnaire was sent to female members of the Polish Society of Gastroenterology and participants of the XX Polish Society of Gastroenterology Congress.</p><p><strong>Results: </strong>The majority of respondents were aged 30-40 years (30.6%) and 40-50 years (29.2%). More female gastroenterologists reside and work in the Masovian Voivodeship (16.7%) than in other regions. The age of completing specialisation is predominantly 30-40 years (76.4%). 37.5% work in cities of more than 500,000 inhabitants. The primary workplaces are gastroenterological wards (66.7%) and endoscopic units (16.7%) within hospitals. Additional workplaces include gastroenterological outpatient clinics (54.9%) and private practices (54.2%). Only 25.7% hold management positions. Common procedures performed include diagnostic gastroscopy (91%), diagnostic colonoscopy (77.1%), and polypectomy (63.2%). 97.9% are satisfied with their specialty choice.</p><p><strong>Conclusions: </strong>Gender discrimination remains prevalent in various aspects of medicine. Nearly half of the female gastroenterologists experience gender-related limitations in their professional roles. Despite progress, significant efforts are needed to raise awareness and promote gender equality to support women in gastroenterology.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 1","pages":"45-48"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diverticular disease increases the risk of acute myocardial infarction.","authors":"Thanathip Suenghataiphorn, Pojsakorn Danpanichkul, Noppachai Siranart, Thitiphan Srikulmontri, Narathorn Kulthamrongsri","doi":"10.5114/pg.2026.160367","DOIUrl":"10.5114/pg.2026.160367","url":null,"abstract":"<p><strong>Introduction: </strong>Diverticular disease is commonly seen among patients with cardiovascular diseases and is linked to adverse outcomes. However, the association between diverticular disease and the risk of acute myocardial infarction (AMI) remains conflicting.</p><p><strong>Aim: </strong>We aim to conduct a systematic review and meta-analysis to summarise the available data on this topic.Methods: We identified potentially eligible studies from the Medline and Embase databases, searching from inception to August 2024, to investigate the association between diverticular disease and the risk of developing AMI. To be included, studies needed to compare incidence of AMI between cohorts with and without diverticular disease. Effect size and 95% confidence intervals (CIs) were combined using the generic inverse variance method. All statistical analyses were performed by Review Manager 5.4.</p><p><strong>Results: </strong>Our meta-analysis included four studies that met the eligibility criteria. There were 898,397 participants, with a mean age of 57 years, and 43% were males. We found that patients with diverticular disease have a 27% increased risk of AMI with a pooled risk ratio (RR) of 1.27 (95% CI: 1.17, 1.37; <i>I</i> ² = 83%; <i>p</i> < 0.001) compared to those without diverticular disease.</p><p><strong>Conclusions: </strong>Our study revealed that diverticular disease is associated with a higher risk of AMI. Emphasising and addressing gastrointestinal health, including diverticular disease, as an important issue, is essential for comprehensive cardiovascular care.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 1","pages":"19-24"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of exocrine pancreatic insufficiency in diabetes mellitus - a multicentre study.","authors":"Roland Kadaj-Lipka, Marta Wynimko, Karolina Borowska, Edward Franek, Agnieszka Mądro, Barbara Skrzydło-Radomańska, Halina Cichoż-Lach, Barbara Włodarczyk, Ewa Małecka-Wojciesko, Elżbieta Czkwianianc, Krystian Adrych, Stanisław Głuszek, Dorota Kozieł, Grażyna Rydzewska","doi":"10.5114/pg.2026.161673","DOIUrl":"10.5114/pg.2026.161673","url":null,"abstract":"<p><strong>Introduction: </strong>Faecal elastase-1 (FE-1) measurement is a widely utilised screening tool for exocrine pancreatic insufficiency (PEI).</p><p><strong>Aim: </strong>The present study aimed to assess the prevalence of PEI in diabetic patients and its relationship with diabetes duration, antidiabetic medication use, body mass index, diabetes type, and comorbidities.</p><p><strong>Material and methods: </strong>A retrospective study was conducted that included 519 patients with type 1 and type 2 diabetes from five medical centres in Poland. The ScheBo^® Pancreatic Elastase-1 Quick™ test was utilised for the measurement of faecal elastase-1 levels. Patients with a history of alcohol abuse, gastrointestinal surgery, or pancreatic cancer were excluded from the study. The medical records of the patients were analysed to obtain clinical data.</p><p><strong>Results: </strong>Among the 519 patients (262 women, 257 men; mean age: 67 years), 20.2% had an FE-1 level < 200 µg/g, indicating PEI. A statistically significant (<i>p</i> > 0.05) higher prevalence of PEI was observed in patients with obesity (BMI > 25 kg/m²). However, no statistically significant association was found between FE-1 levels and factors such as diabetes duration, antidiabetic medication use, or metabolic control. PEI is prevalent in diabetic patients, with a prevalence exceeding 20%. The findings of this study support the rationale for screening for FE-1 in diabetes and suggest that enzyme replacement therapy may be a viable treatment option for patients diagnosed with PEI.</p><p><strong>Conclusions: </strong>The results of this study imply that PEI is not a late complication of diabetes but may occur independently of disease duration.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 2","pages":"160-165"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentre retrospective real-world evidence study evaluating the effectiveness and safety of mirikizumab in patients with moderately to severely active ulcerative colitis.","authors":"Łukasz Lamparski, Katarzyna Karłowicz, Edyta Tulewicz-Marti, Dagmara Mahadea, Liliana Łykowska-Szuber, Joanna Sarbinowska, Maciej Gonciarz, Bartosz Kabała, Dawid Szkudłapski, Iwona Zawada, Maria Tarnowska, Aleksandra Sójka, Katarzyna Neubauer, Magdalena Stojek, Krystian Adrych, Tomasz Romańczyk, Marcin Romańczyk, Anna Chaber-Ciopińska, Edyta Zagórowicz, Agata Michalak, Halina Cichoż-Lach, Danuta Domżał-Magrowska, Anna Boduła, Ewa Małecka-Wojciesko, Ewa Walecka-Kapica, Anita Gąsiorowska, Agnieszka Pietraszek, Krzysztof Pol, Sylwia Nemeczek, Rafał Filip, Magdalena Gawron-Kiszka, Joanna Musialik, Agnieszka Klufczyńska, Grażyna Piotrowicz, Anna Pietrzak, Małgorzata Zwolińska-Wcisło, Jarosław Daniluk, Maria Kopertowska-Majchrzak, Jarosław Koza, Maria Kłopocka, Grażyna Rydzewska, Konrad Lewandowski","doi":"10.5114/pg.2026.161906","DOIUrl":"10.5114/pg.2026.161906","url":null,"abstract":"<p><strong>Introduction: </strong>Mirikizumab (MIRI), a selective IL-23 p19 inhibitor, has demonstrated efficacy in randomised trials in moderate to severe ulcerative colitis (UC), but real-world data remain limited, particularly in highly treatment-exposed populations.</p><p><strong>Aim: </strong>To assess the real-world effectiveness and safety of MIRI in adults with moderately to severely active UC.</p><p><strong>Material and methods: </strong>This retrospective multicentre study included 257 adults with UC initiating MIRI before 31 January 2026 across 21 Polish centres. Induction consisted of intravenous MIRI 300 mg at weeks 0, 4, and 8, with optional extension to week 24 in cases of insufficient response. Disease activity was assessed at baseline and at weeks 12 and 24 using clinical, endoscopic, and laboratory parameters. Safety was evaluated by recording adverse events (AE) and serious adverse events (SAE).</p><p><strong>Results: </strong>Most patients had prior exposure to advanced therapy, and 54.1% underwent extended induction. Significant improvement was observed at weeks 12 and 24 across all parameters. Among evaluable patients, clinical remission was 31.7% at week 12 and 41.8% at week 24, while clinical response was 76.2% and 79.3%, respectively. Endoscopic remission was 9.5% and 18.5%, whereas endoscopic response was 67.1% and 64.8%, respectively. Corticosteroid-free clinical remission was 23.1% and 26.4%. AE occurred in 9.1% and 14.1% of patients, and SAE in 2.6% and 6.6%.</p><p><strong>Conclusions: </strong>In this large real-world study with predominantly advanced therapy-exposed UC, MIRI was associated with significant clinical, endoscopic, and biochemical improvement through weeks 12 and 24, with a favourable safety profile.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 2","pages":"148-159"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vedolizumab as a first-choice biological treatment of Crohn's disease in a patient with paraganglioma of the nervous system.","authors":"Patrycja Szałwińska, Wojciesko Ewa Malecka-","doi":"10.5114/pg.2026.160317","DOIUrl":"10.5114/pg.2026.160317","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 1","pages":"108-110"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver function disorders in pregnancy: physiology or pathology?","authors":"Wiktoria Sielwanowska-Lasek, Agnieszka Mądro","doi":"10.5114/pg.2026.160319","DOIUrl":"10.5114/pg.2026.160319","url":null,"abstract":"<p><p>The occurrence of abnormal liver function markers in pregnancy does not always indicate pathology. Many biochemical changes, such as increased alkaline phosphatase at the end of pregnancy or decreased albumin and bilirubin, are physiological and do not cause concern for the health of the pregnant woman and child. However, due to their similarity to the symptoms of liver diseases, their interpretation is a diagnostic challenge. It is important to take into account the characteristic clinical course of individual diseases and the stage of pregnancy in which they most often occur. This article discusses liver diseases specific to pregnancy, such as hyperemesis gravidarum, HELLP syndrome, preeclampsia and eclampsia, intrahepatic cholestasis of pregnancy, and acute fatty liver disease of pregnancy, as well as diseases independent of it, such as autoimmune hepatitis (AIH), primary biliary cirrhosis, and primary sclerosing cholangitis. Although symptoms of some diseases may improve during pregnancy, there is a risk of exacerbations in AIH, especially in the perinatal period, which requires close monitoring and adjustment of immunosuppressive therapy. Differential diagnosis should also include drug-induced liver injury and viral infections. A thorough medical history and analysis of symptoms are important. Early diagnosis and rapid therapeutic action in the discussed diseases are crucial to minimise the risk of complications.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 1","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13085046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double guidewire cannulation technique versus cannulation over pancreatic stent after unintended pancreatic duct cannulation.","authors":"Mohammed Hussien Ahmed, Eslam Elshennawy, Aya M Mahros","doi":"10.5114/pg.2026.161877","DOIUrl":"10.5114/pg.2026.161877","url":null,"abstract":"<p><strong>Introduction: </strong>Selective biliary cannulation is essential for successive endoscopic intervention.</p><p><strong>Aim: </strong>To compare the efficacy and safety of the double-guidewire technique (DGT) versus cannulation over a pancreatic stent (CPS) following unintended pancreatic duct cannulation during endoscopic retrograde cholangiopancreatography (ERCP) in real-world clinical practice.</p><p><strong>Material and methods: </strong>We conducted a prospective study including 103 patients who underwent ERCP between June and December 2024 at Kafrelsheikh University Hospital. Patients with difficult biliary cannulation and unintentional guidewire entry into the pancreatic duct during standard wire-guided cannulation were included. In these cases, either the DGT or CPS approach (with or without needle-knife sphincterotomy) was employed. Outcomes such as cannulation success time, number of attempts, and the need for precut sphincterotomy were recorded and analysed.</p><p><strong>Results: </strong>The CPS group had a significantly higher requirement for precut sphincterotomy (88.6%) compared to the DGT group (33.3%) (<i>p</i> < 0.0001). A higher proportion of small papillae was observed in the CPS group (52.9%) versus the DGT group (47.1%). Time to successful biliary cannulation was significantly shorter in the DGT group (8.27 ±4.8 min) compared to the CPS group (11.84 ±3.2 min) (<i>p</i> = 0.0031).</p><p><strong>Conclusions: </strong>The CPS technique required significantly more precut sphincterotomies than DGT. While the number of cannulation attempts was similar between techniques, DGT allowed for faster cannulation. CPS may reduce the risk of complications such as post-ERCP pancreatitis, but DGT appears more time-efficient. Selection of the appropriate technique should be based on individual anatomical and procedural factors.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"21 2","pages":"178-184"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}